Nasus Pharma

Company Overview

Snapshot

Founded in May 2019 by Udi Gilboa and Dr. Dalia Meggido, Nasus Pharma operates with 1–10 employees. The company has raised $25 million across two funding rounds. In August 2025, Nasus Pharma completed its Initial Public Offering and listed on the NYSE.

Business overview

Nasus Pharma is a biopharmaceutical company focused on developing intranasal powder products for acute emergency situations, leveraging its proprietary microsphere technology. The company's portfolio includes programs for intranasal naloxone, intranasal epinephrine, and other preclinical proof-of-concept initiatives. Serving the healthcare and life sciences sectors, Nasus Pharma aims to provide non-invasive drug delivery solutions for critical medical needs in markets such as the United States, Israel, and Europe.

Strategic signal

In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002 Intranasal Epinephrine Powder, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen® with an accelerated speed to therapeutic threshold. This clinical validation signals a strong potential for NS002 to become a leading treatment for anaphylaxis, positioning Nasus Pharma for further advancement towards pivotal studies and potential market entry.

Company Intelligence Q&A

When did Nasus Pharma complete its Initial Public Offering?

Nasus Pharma completed its Initial Public Offering in August 2025, listing on the NYSE.

What was a key finding from the Phase 2 clinical study of NS002 Intranasal Epinephrine Powder?

In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen® with an accelerated speed to therapeutic threshold.

What recent leadership appointment did Nasus Pharma make?

In November 2025, Nasus Pharma strengthened its leadership team by appointing Eyal Rubin as Executive Vice President and Chief Financial Officer.

What was the outcome of the preclinical study for Intranasal Ondansetron (NS003)?

In June 2026, Nasus Pharma announced positive results from a preclinical pharmacokinetic and safety study of Intranasal Ondansetron (NS003).

What was the purpose of the virtual KOL event hosted by Nasus Pharma in June 2026?

In June 2026, Nasus Pharma hosted a virtual Key Opinion Leader (KOL) event to discuss NS002 for the treatment of anaphylaxis.